Excessive Pharmaceutical Pricing in the US and Europe –Similar diseases, different treatments?
Panel
Panel 5: Patient Exhaustion and Competition
Moderator
Gary Pulsinelli, Associate Professor of Law, University of Tennessee Law
Description
Recently excessive pharmaceutical pricing has gained renewed attention by courts, competition authorities and political forces on both sides of the Atlantic. Balancing the public demand for affordable and accessible health-care with the need for sufficient incentives and a sustainable innovation system in the field of medicines also attracts a great deal of policy and scholarly attention. Facing what seems to be a revival of competition law in this highly sensitive and complex environment, this presentation depicts recent case law and policy developments and discusses the different approaches and position taken in the evolving US and European debates.
Location
Pacific McGeorge School of Law, Lecture Hall, 3200 Fifth Ave., Sacramento, CA
Excessive Pharmaceutical Pricing in the US and Europe –Similar diseases, different treatments?
Pacific McGeorge School of Law, Lecture Hall, 3200 Fifth Ave., Sacramento, CA
Recently excessive pharmaceutical pricing has gained renewed attention by courts, competition authorities and political forces on both sides of the Atlantic. Balancing the public demand for affordable and accessible health-care with the need for sufficient incentives and a sustainable innovation system in the field of medicines also attracts a great deal of policy and scholarly attention. Facing what seems to be a revival of competition law in this highly sensitive and complex environment, this presentation depicts recent case law and policy developments and discusses the different approaches and position taken in the evolving US and European debates.
Speaker Bio
Timo Minssen is Professor of Law at the University of Copenhagen (UCPH) and the Founding Director of UCPH's Center for Advanced Studies in Biomedical Innovation Law (CeBIL). He specializes in the interface of Intellectual Property, Competition and Regulatory Law with a special focus on new technologies in the health & life sciences, such as AI and big data-driven precision medicine. His studies involve a plethora of legal issues emerging in the lifecycle of biotechnological and medical products and processes - from the regulation of research and incentives for innovation to technology transfer and commercialization.
At UCPH he had lead several large interdisciplinary research projects in synthetic biology, precision medicine and research infrastructures. At present, he is the principal investigator and grant holder of a large research program in biomedical innovation law, funded by the Novo Nordisk Foundation. Anchored in Copenhagen it involves close collaboration with international core partners, such as Harvard Law School, Harvard Medical School, as well as the Universities of Cambridge and Michigan. Timo has also been the legal expert advisory board member of EU Commission studies of the pharmaceutical sector. He is the steering committee member of the Danish Association for the Protection of Industrial Property and scientific advisory board member of the Copenhagen Centre for Regulatory Sciences (CORS), where he works inter alia with the protection and regulation of biologics and biosimilars.
Timo holds a German law degree from the University of Göttingen, as well as biotech & IP -related LL.M. M.I.C.L., LL.Lic. and LL.D. degrees from Lund & Uppsala University. He has been Visiting Research Fellow at the Universities of Cambridge & Oxford, Harvard Law School, Chicago-Kent College of Law, and at the Max Planck Institute for Innovation & Competition. Moreover, he was trained in the German Court system and at the European Patent Office.